Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment

被引:50
|
作者
Zeerleder, Sacha [1 ,2 ,3 ]
Levi, Marcel [4 ]
机构
[1] Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands
[2] AMC, Landsteiner Lab, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1012 WX Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1012 WX Amsterdam, Netherlands
关键词
Acquired angioedema; bradykinin; bradykinin-receptor; 2; C1-inhibitor; factor VII-activating protease; factor XII; hereditary angioedema; high-molecular kininogen; kallikrein; low-molecular kininogen; C1 INHIBITOR CONCENTRATE; NONPEPTIDE B-2 ANTAGONIST; KALLIKREIN-KININ SYSTEM; FACTOR-XII; C1-ESTERASE INHIBITOR; ESTERASE INHIBITOR; TRANEXAMIC ACID; MISSENSE MUTATIONS; CLINICAL-FEATURES; SERINE-PROTEASE;
D O I
10.3109/07853890.2016.1162909
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Uncontrolled generation of bradykinin (BK) due to insufficient levels of protease inhibitors controlling contact phase (CP) activation, increased activity of CP proteins, and/or inadequate degradation of BK into inactive peptides increases vascular permeability via BK-receptor 2 (BKR2) and results in subcutaneous and submucosal edema formation. Hereditary and acquired angioedema due to C1-inhibitor deficiency (C1-INH-HAE and -AAE) are diseases characterized by serious and potentially fatal attacks of subcutaneous and submucosal edemas of upper airways, facial structures, abdomen, and extremities, due to inadequate control of BK generation. A decreased activity of C1-inhibitor is the hallmark of C1-INH-HAE (types 1 and 2) due to a mutation in the C1-inhibitor gene, whereas the deficiency in C1-inhibitor in C1-INH-AAE is the result of autoimmune phenomena. In HAE with normal C1-inhibitor, a significant percentage of patients have an increased activity of factor XIIa due to a FXII mutation (FXII-HAE). Treatment of C1-inhibitor-dependent angioedema focuses on restoring control of BK generation by inhibition of CP proteases by correcting the balance between CP inhibitors and BK breakdown or by inhibition of BK-mediated effects at the BKR2 on endothelial cells. This review will address the pathophysiology, clinical picture, diagnosis and available treatment in C1-inhibitor-dependent angioedema focusing on BK-release and its regulation.Key MessagesInadequate control of bradykinin formation results in the formation of characteristic subcutaneous and submucosal edemas of the skin, upper airways, facial structures, abdomen and extremities as seen in hereditary and acquired C1-inhibitor-dependent angioedema.Diagnosis of hereditary and acquired C1-inhibitor-dependent angioedema may be troublesome as illustrated by the fact that there is a significant delay in diagnosis; a certain grade of suspicion is therefore crucial for quick diagnosis.Submucosal edema formation in hereditary and acquired C1-inhibitor-dependent angioedema is potentially life threatening and can occur at any age.To date effective therapies for acute and prophylactic treatment are available.
引用
收藏
页码:256 / 267
页数:12
相关论文
共 50 条
  • [1] Hereditary Angioedema with Normal C1 Inhibitor Update on Evaluation and Treatment
    Magerl, Markus
    Germenis, Anastasios E.
    Maas, Coen
    Maurer, Marcus
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (03) : 571 - +
  • [2] Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment
    Zuraw, Bruce L.
    Bork, Konrad
    Bouillet, Laurence
    Christiansen, Sandra C.
    Farkas, Henriette
    Germenis, Anastasios E.
    Grumach, Anete S.
    Kaplan, Allen
    Lopez-Lera, Alberto
    Magerl, Markus
    Riedl, Marc A.
    Adatia, Adil
    Banerji, Aleena
    Betschel, Stephen
    Boccon-Gibod, Isabelle
    Bova, Maria
    Boysen, Henrik Balle
    Caballero, Teresa
    Cancian, Mauro
    Castaldo, Anthony J.
    Cohn, Danny M.
    Corcoran, Deborah
    Drouet, Christian
    Fukunaga, Atsushi
    Hide, Michihiro
    Katelaris, Constance H.
    Li, Philip H.
    Longhurst, Hilary
    Peter, Jonny
    Psarros, Fotis
    Reshef, Avner
    Ritchie, Bruce
    Selva, Christine N.
    Zanichelli, Andrea
    Maurer, Marcus
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2025, 68 (01)
  • [3] Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency
    Zanichelli, Andrea
    Montinaro, Vincenzo
    Triggiani, Massimo
    Arcoleo, Francesco
    Visigalli, Debora
    Cancian, Mauro
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (02) : 103 - 110
  • [4] Cinryze™ (C1-inhibitor) for the treatment of hereditary angioedema
    Gompels, Mark M.
    Lock, Robert John
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (05) : 569 - 573
  • [5] Acquired Angioedema associated with hereditary Angioedema due to C1 inhibitor deficiency
    Guilarte, M.
    Luengo, O.
    Nogueiras, C.
    Labrador-Horrillo, M.
    Munoz, E.
    Lopez, A.
    Cardona, V.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2008, 18 (02) : 126 - 130
  • [6] Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity
    Shamanaev, Aleksandr
    Dickeson, S. Kent
    Ivanov, Ivan
    Litvak, Maxim
    Sun, Mao-Fu
    Kumar, Sunil
    Cheng, Quifang
    Srivastava, Priyanka
    He, Tracey Z.
    Gailani, David
    FRONTIERS IN PHYSIOLOGY, 2023, 14
  • [7] The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
    Cicardi, M.
    Zanichelli, A.
    CURRENT MOLECULAR MEDICINE, 2010, 10 (04) : 354 - 360
  • [8] Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2
    Fijen, Laure M.
    Bork, Konrad
    Cohn, Danny M.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2021, 61 (01) : 66 - 76
  • [9] Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy
    Kaplan, Allen P.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (05) : 918 - 925
  • [10] Acquired and hereditary forms of recurrent angioedema: Update of treatment
    Bork, K.
    ALLERGOLOGIE, 2013, 36 (03) : 108 - 119